What Will Happen to CRISPR Therapeutics AG (CRSP) Next? The Stock Just Increased A Lot

April 19, 2018 - By Ellis Scott

The stock of CRISPR Therapeutics AG (NASDAQ:CRSP) is a huge mover today! The stock increased 7.89% or $4.2 during the last trading session, reaching $57.42. About 2.10M shares traded or 83.77% up from the average. CRISPR Therapeutics AG (NASDAQ:CRSP) has risen 144.93% since April 19, 2017 and is uptrending. It has outperformed by 133.38% the S&P500.
The move comes after 5 months positive chart setup for the $2.71B company. It was reported on Apr, 19 by Barchart.com. We have $60.29 PT which if reached, will make NASDAQ:CRSP worth $135.40M more.

Analysts await CRISPR Therapeutics AG (NASDAQ:CRSP) to report earnings on May, 10. They expect $-0.67 earnings per share, down 24.07 % or $0.13 from last year’s $-0.54 per share.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 gene-editing platform in Switzerland. The company has market cap of $2.71 billion. The CRISPR/Cas9 technology allows for changes to genomic DNA. It currently has negative earnings. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies.

CRISPR Therapeutics AG (NASDAQ:CRSP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.